VEGF Expression is Associated with Negative Estrogen Receptor Status in Patients with Breast Cancer (original) (raw)
Related papers
Expression of Vegf in Breast Cancer
International Journal of Advanced Research, 2019
Breast Cancer is the most frequent cancer in India. Tumor angiogenesis has been considered as a crucial step in the cancer development and progression. Vascular endothelial growth factor (VEGF) is one important prognostic marker in patients with breast cancer .The aim of the study is to see the expression of VEGF in breast cancers by immunohistochemistry.. Materials and methods: Formalin fixed paraffin embedded sections of 100 cases of malignant breast lesions were taken up for the study and subjected to immunohistochemistry using VEGF. Results: The intensity of VEGF immunostaining in malignant breast lesions was evaluated and scoring was graded as 0,1+,2+,3+ and 4+. Statistical analysis was performed with Chi-Square test and significant differences were noted between these 3 groups (p value< 0.05). Conclusion: VEGF expression correlated well with the grade and stages of tumor indicating that VEGF positive tumors are biologically aggressive and are associated with poor prognosis.
Correlation of VEGF expression with prognostic factors of breast carcinoma
Bangladesh Journal of Medical Science, 2019
Background: Breast carcinoma is the most common malignant tumour and leading cause of cancer death among women worldwide. VEGF being a powerful mediator of angiogenesis, plays a major role in local growth as well as metastasis of many solid tumours including breast carcinoma. Objective: This study aimed to evaluate the significance of VEGF expression in breast cancer and its correlation with prognostic parameters. Materials and methods: This study was conducted over a period of one year (February 2015 to January 2016). VEGF expression was evaluated in 57 histologically diagnosed cases of breast carcinoma with known ER and HER-2/neu status. Result: Among 57 cases 52(91.2%) were positive for VEGF. Positive ER expression was seen in 39 cases which is 64.8% of total cases. 54% of the total cases were positive for HER-2/neu. VEGF expression was positively correlated (P value <0.05) with tumour grade, tumour size and negatively correlated with ER (p<0.005) and HER-2/neu (p<0.005)...
International Journal of Cancer, 1997
Studies have shown that microvessel density influences breast-cancer prognosis. Since tumor angiogenesis is considered to be substantially affected by the excretion of vascular endothelial growth factor (VEGF) from tumor cells, we examined whether VEGF concentration is different in malignant and in non-malignant breast tissue. It was also of interest to discover whether intratumoral VEGF concentration influences disease-free survival (DFS) of breast-cancer patients. Analysis is based on 120 tissue specimens taken from breast fibromas (n 5 23), normal epithelial breast tissue adjacent to fibromas (n 5 8) and invasive breast cancer (n 5 89). VEGF concentration was quantified by using an immunoassay. Microvessel density was determined by immunostaining for factor-VIII-related antigen. Median VEGF concentration is given in pg/mg protein (25%-quantile-75%-quantile) and it was 0 (0-1.8) in normal breast tissue, 9.8 (0.52-43.0) in fibromas and 130.4 (50.8-362.2) in invasive carcinomas. A univariate Cox model revealed that node status, tumor size, estrogen-receptor concentration, histological grading and microvessel density were prognostic factors for disease-free survival in breast cancer. We found a significant correlation between VEGF concentration and microvessel count, but VEGF concentration did not significantly influence diseasefree survival. Although VEGF protein was found at a significantly higher concentration in malignant than in nonmalignant tissue, determination of intratumoral VEGF protein by an enzyme immunoassay was not prognostically relevant in our patient population. Int. J. Cancer 74:455-458, 1997.
The International Journal of Biological Markers, 2004
VEGF is a specific mitogen and survival factor for endothelial cells and a key promoter of angiogenesis in physiological and pathological conditions. Nevertheless, VEGF tissue evaluation in cancer patients as a prognostic factor compared to the conventional histological and biological parameters is still controversial. In this case-control study, tissue VEGF was retrospectively determined by immunohistochemistry and related to T, N, ER, PgR, c-erbB-2, p53, MIB-1 and cyclin D1 in 129 breast cancer patients. Seventy-four of these patients had developed distant metastases postoperatively. The remaining 55 patients had remained disease-free >10 years after surgery. In 17 (13%) of the 129 patients (six with distant metastases and eleven disease-free) tissue and plasma VEGF were concomitantly evaluated. In univariate analysis no significant differences in VEGF and tumor size were found between metastatic and disease-free patients, whereas there were significant differences in N, ER, PgR, c-erbB-2, p53, MIB-1 and cyclin D1 (p ranging from 0.001 to 0.0001). In multivariate analysis VEGF showed less significance than N, ER, c-erbB-2, MIB-1 and cyclin D1 (p=0.012, p=0.007, p=0.005, p=0.005, p=0.002 and p=0.001, respectively). VEGF was a significant unfavorable prognostic indicator only in the N+ subset (p=0.015), while ER (p=0.05 and p=0.021) and MIB-1 (p=0.031 and p=0.022) were significant in both the N+ and N-subgroups. In multivariate analysis in the 74 metastatic cases VEGF did not show any significance in relation to disease-free interval and overall survival from the time of mastectomy and from the time of relapse, whereas N and PgR did (p ranging from 0.018 to 0.001). In conclusion, tissue VEGF does not seem a suitable candidate to replace conventional histological and other common biological prognostic factors in breast cancer.
Serum VEGF levels in women with a benign breast tumor or breast cancer
Breast Cancer Research and Treatment, 1999
Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis and vascular permeability. Many types of malignant human tumors have been shown to produce VEGF. Recently, increased serum concentrations of VEGF (S-VEGF) have been reported in patients with various types of cancer, and high S-VEGF levels have also been associated with unfavorable prognosis. We have now measured S-VEGF in sera taken from 105 patients with a benign breast tumor or breast cancer. None of the women with a benign breast tumor had S-VEGF higher than 328 pg/ml (median, 57 pg/ml) whereas S-VEGF levels in metastatic breast cancer ranged from 7 to 1347 pg/ml (median, 186 pg/ml; P = 0.0018), and in locoregional breast cancer from 11 to 539 pg/ml (median, 104 pg/ml; P = 0.13). S-VEGF was higher in patients with locoregional ductal cancer (median, 107 pg/ml) than in those with locoregional lobular cancer (median, 44 pg/ml; P = 0.029) or in patients with benign breast tumor (median, 57 pg/ml; P = 0.033). Patients with metastatic cancer undergoing therapy had lower S-VEGF than those who had symptomatic treatment only (P = 0.021). The results indicate that dissemination of breast cancer may be accompanied by an elevation of circulating VEGF and that primary ductal cancers are associated with higher S-VEGF levels than lobular cancers or benign breast lesions.
Vascular endothelial growth factor –A (VEGF-A) expression as a prognostic factor in breast cancer
IP innovative publication pvt ltd, 2020
Objective: To assess the expression of VEGF-A in breast cancer patient and to find an association between VEGF- A overexpression and the clinicopathologic features. Materials and Methods: The study was conducted from January 2010 through 2016. Formalin-fixed, paraffin-embedded blocks from 64 patients with breast cancer were included in this study. S treptavidinbiotin method was employed for immunohistochemical detection of VEGF. Results: The detection rate of VEGF was 93.5%. There was a significant difference in the immunoexpression of VEGF A between the different histological types of carcinoma. However, no significant differen ces were noted among age groups, tumor sizes, perineural invasion and overall survival. Conclusion: In our study, VEGF overexpression was positiv ely associated with only the histological type of breast cancer. Further studies involving patients with advanced diseases are required to establish an association between the VEGF-A over expression and survival outcomes and to use it as a prognostic biomarker.
Polish Journal of Pathology, 2012
The aim of the study was to assess the value of vascular endothelial growth factor (VEGF) measurements in breast cancer patients with respect to recognized clinicopathological prognostic factors. The study was conducted in 87 women with histologically confirmed breast cancer who underwent surgical treatment and 37 healthy women. Vascular endothelial growth factor concentration levels in the blood samples of patients were correlated with the size of the primary tumor, lymph nodes in the armpit, cancer stage, histological type, grading, multifocality, status of estrogen and progesterone receptors and HER-2 protein expression. Statistical analysis did not show any correlation between concentrations of VEGF and any of the selected parameters. The comparison of VEGF concentrations showed a slightly raised level of VEGF in women with the disease as opposed to the healthy subjects but the differences were not statistically significant (p = 0.472). Similar results were obtained for marker CEA (p = 0.09), while the level of Ca 15-3 in both groups differed significantly (p < 0.001) reaching higher values in the patients with diagnosed breast cancer. Vascular endothelial growth factor concentrations in breast cancer patients do not correlate with recognized clinicopathological prognostic factors and CEA and Ca 15-3 markers, which does not preclude the potential role of VEGF as an independent prognostic factor.
Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2008
VEGF is a potent mitogen for endothelial cells and also acts in an autocrine and paracrine manner for development of tumor cells in breast cancer. Correlations between VEGF and some clinicopathologic findings were largely studied but results were controversial. Our purpose was to find if VEGF could be used as individual prognostic factor in invasive breast carcinoma. We included in our study 35 cases of invasive breast carcinoma, which were immunostained for VEGF using monoclonal antibodies anti-VEGF clone VG1. The assessment of VEGF expression used a scoring system, which included an intensity parameter correlated with percent of positive tumor cells. We found positive correlation between ductal invasive carcinoma type of breast cancer and VEGF expression. In addition, presence of inflammation associated with breast malignancies had a significant correlation with VEGF positive staining. Because of these correlations found in our study, we concluded that VEGF could not be used as in...
The Determination of VEGF and MVD, among Patients with Primary Breast Cancer
Pathology & Oncology Research, 2008
The purpose of the study was to ascertain the value of assessment of vascular endothelial growth factor (VEGF) levels and microvessel density, and to search for correlations between them, in women with breast cancer. The assessment considered factors such as the stage of clinical disease advancement-according to International Union Against Cancer, the grade of histological malignancy, status of axillary lymph nodes and the size of the primary tumour. The concentration of VEGF was assessed in the plasma of 103 women with breast cancer, using an immunoenzymatic method (Quantikine test of R&D Systems). Assessment of microvessel density was performed using histopathological immunoperoxidase methods, using an anti-von Willebrand factor antibody (DAKO A/S). A statistically significant relationship was found between rising VEGF levels and microvessel density in women with breast cancer, when compared to values from a control group. A correlation was found between VEGF concentration and microvessel density (MVD) values. Statistically significant differences were found between VEGF levels of patients in stages I, II and III of clinical disease advancement.